Net Benefit of Antithrombotic Therapy in AF and CKD

109 30
Net Benefit of Antithrombotic Therapy in AF and CKD

Conclusions


We have found that among AF patients, CKD was associated with a higher risk of stroke/TE across stroke risk (CHA2DS2-VASc) strata, most notably among RRT patients. In RRT patients with CHA2DS2-VASc score ≥2, warfarin was associated with a net clinical benefit, as it was associated with a lower risk of all-cause mortality. In non-end-stage CKD patients with CHA2DS2-VASc score ≥2, warfarin was associated with a net clinical benefit, as it was associated with a lower risk of all-cause mortality, a lower risk of cardiovascular death, and a lower risk of the composite outcome of fatal stroke/fatal bleeding, respectively. These observations provide guidance for the optimal use of antithrombotic therapy in AF patients with CKD.

Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.
You can unsubscribe at any time

Leave A Reply

Your email address will not be published.